



Express Mail Label: EV109727513US
Date of Deposit: January 31, 2003



02-03-03

Attorney Docket N. : 24492-006



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Stephen J. Brand
SERIAL NUMBER: 10/044,048 EXAMINER: Not Yet Assigned
FILING DATE: January 11, 2002 ART UNIT: 1619
FOR: Prolonged Efficacy of Islet Neogenesis Therapy Methods With a
Gastrin/CCK Receptor Ligand and an EGF Receptor Ligand Composition in
Subjects with Preexisting Diabetes

January 31, 2003
Boston, Massachusetts

Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

1. Supplemental Information Disclosure Statement (2 pages) in duplicate;
2. Modified Form 1449/PTO (1 page) in duplicate;
3. Copies of cited references A4; and B3-B4; and C5; and
4. Return Postcard.

No fee is believed to be due. However, if any fees are to be assessed, the Commissioner is hereby authorized to charge the balance due to the undersigned's account, Deposit Account No. 50-0311, Reference No. 24492-006. A duplicate copy of this transmittal letter is enclosed.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at 617/542-6000, Boston, Massachusetts.

Respectfully submitted,

Sonia K. Guterman, Esq. (Reg. No. 44,729)
Attorney for Applicants

c/o MINTZ, LEVIN, COHN, FERRIS
GLOVSKY AND POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

TRA 1759565v1




30623

PATENT TRADEMARK OFFICE

Express Mail Label: EV109727513US
Date of Deposit: January 31, 2003



Attorney Docket No. : 24492-086



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Stephen J. Brand
SERIAL NUMBER: 10/044,048 EXAMINER: Not Yet Assigned
FILING DATE: January 11, 2002 ART UNIT: 1619
FOR: Prolonged Efficacy of Islet Neogenesis Therapy Methods With a Gastrin/CCK Receptor
Ligand and an EGF Receptor Ligand Composition in Subjects with Preexisting Diabetes
January 31, 2003
Boston, Massachusetts

BOX IDS
Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicant hereby makes of record the documents listed on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. The order of presentation of the references should not be construed as an indication of the importance of the references.


This Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits in the above-identified case. Accordingly, no fee or certification is required as set forth in 37 C.F.R. §1.97.

A copy of each of the above-identified information is enclosed unless otherwise indicated on the attached modified Form PTO-1449. It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed Form PTO-1449 to evidence that the cited information has been fully considered by the PATENT AND TRADEMARK OFFICE during the examination of this application.

Applicant: Stephen J. Brand
U.S.S.N.: 10/044,048

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311 (Reference No. 24492-006).

Respectfully submitted,

A handwritten signature in cursive script, reading "Sonia K. Guterman".

Sonia K. Guterman, Esq. (Reg. No. 44,729)

Attorney for the Applicant

c/o MINTZ, LEVIN, COHN, FERRIS,

GLOVSKY and POPEO, P.C.

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000

Fax: (617) 542-2241

TRA 1759573v1

Express Mail N .: EV109727513US
Date of Deposit: January 31, 2003



RECEIVED
Page 1 of 1
FEB 04 2003
TECH CENTER 1600/2900
PTO/SB (12-97)

Please type a plus sign (+) in this box



Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/044,048
	Filing Date	January 11, 2003
	First Named Inventor	Brand
	Group Art Unit	1619
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	24492-006

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Publication Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A4	2002/0081285	27 June 2002	Parikh, I. et al.			20 December 2001

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
	B3	WO	95/19785	Research Triangle Pharmaceuticals, Ltd.	27 July 1995		
	B4	WO	00/44400	RTP Pharma, Inc.	3 August 2000		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C5	International Search Report for PCT US 02/00685, mailed 27 December 2002.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

TRA 1759503v1